RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance

Journal:

Nature Communications

Published:

2026-01-12

DOI:

10.1038/s41467-025-67315-1

Affiliations:

8

Authors:

11

Go to article

Institutions	Authors	Share
Vanderbilt University (VU), United States of America (USA)	4.250000	0.39
Vanderbilt University Medical Center (VUMC), United States of America (USA)	4.000000	0.36
VA Tennessee Valley Healthcare System, United States of America (USA)	2.250000	0.20
University of Manitoba, Canada	0.250000	0.02
CancerCare Manitoba (CCMB), Canada	0.250000	0.02

Interested in Oncology and Carcinogenesis?